Cargando…
Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors
A new series of homosulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) possessing various substitution patterns and moieties in the 7, 8 or 9 position of the heterocylic ring were prepared by original procedures and investigated for the inhibition of four physiologically relevant carbonic anhydras...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896485/ https://www.ncbi.nlm.nih.gov/pubmed/31790605 http://dx.doi.org/10.1080/14756366.2019.1695795 |
_version_ | 1783476788843773952 |
---|---|
author | Pustenko, Aleksandrs Nocentini, Alessio Balašova, Anastasija Alafeefy, Ahmed Krasavin, Mikhail Žalubovskis, Raivis Supuran, Claudiu T. |
author_facet | Pustenko, Aleksandrs Nocentini, Alessio Balašova, Anastasija Alafeefy, Ahmed Krasavin, Mikhail Žalubovskis, Raivis Supuran, Claudiu T. |
author_sort | Pustenko, Aleksandrs |
collection | PubMed |
description | A new series of homosulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) possessing various substitution patterns and moieties in the 7, 8 or 9 position of the heterocylic ring were prepared by original procedures and investigated for the inhibition of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human (h) hCA I, II, IX and XII. The 8-substituted homosulfocoumarins were the most effective hCA IX/XII inhibitors followed by the 7-substituted derivatives, whereas the substitution pattern in position 9 led to less effective binders for the transmembrane, tumour-associated isoforms IX/XII. The cytosolic isoforms hCA I and II were not inhibited by these compounds, similar to the sulfocoumarins/coumarins investigated earlier. As hCA IX and XII are validated anti-tumour targets, with one sulphonamide (SLC-0111) in Phase Ib/II clinical trials, finding derivatives with better selectivity for inhibiting the tumour-associated isoforms over the cytosolic ones, as the homosulfocoumarins reported here, is of crucial importance. |
format | Online Article Text |
id | pubmed-6896485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-68964852019-12-13 Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors Pustenko, Aleksandrs Nocentini, Alessio Balašova, Anastasija Alafeefy, Ahmed Krasavin, Mikhail Žalubovskis, Raivis Supuran, Claudiu T. J Enzyme Inhib Med Chem Research Paper A new series of homosulfocoumarins (3H-1,2-benzoxathiepine 2,2-dioxides) possessing various substitution patterns and moieties in the 7, 8 or 9 position of the heterocylic ring were prepared by original procedures and investigated for the inhibition of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human (h) hCA I, II, IX and XII. The 8-substituted homosulfocoumarins were the most effective hCA IX/XII inhibitors followed by the 7-substituted derivatives, whereas the substitution pattern in position 9 led to less effective binders for the transmembrane, tumour-associated isoforms IX/XII. The cytosolic isoforms hCA I and II were not inhibited by these compounds, similar to the sulfocoumarins/coumarins investigated earlier. As hCA IX and XII are validated anti-tumour targets, with one sulphonamide (SLC-0111) in Phase Ib/II clinical trials, finding derivatives with better selectivity for inhibiting the tumour-associated isoforms over the cytosolic ones, as the homosulfocoumarins reported here, is of crucial importance. Taylor & Francis 2019-12-02 /pmc/articles/PMC6896485/ /pubmed/31790605 http://dx.doi.org/10.1080/14756366.2019.1695795 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Pustenko, Aleksandrs Nocentini, Alessio Balašova, Anastasija Alafeefy, Ahmed Krasavin, Mikhail Žalubovskis, Raivis Supuran, Claudiu T. Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors |
title | Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors |
title_full | Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors |
title_fullStr | Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors |
title_full_unstemmed | Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors |
title_short | Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors |
title_sort | aryl derivatives of 3h-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896485/ https://www.ncbi.nlm.nih.gov/pubmed/31790605 http://dx.doi.org/10.1080/14756366.2019.1695795 |
work_keys_str_mv | AT pustenkoaleksandrs arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors AT nocentinialessio arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors AT balasovaanastasija arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors AT alafeefyahmed arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors AT krasavinmikhail arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors AT zalubovskisraivis arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors AT supuranclaudiut arylderivativesof3h12benzoxathiepine22dioxideascarbonicanhydraseinhibitors |